PMC:7299399 / 19432-19993 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T89","span":{"begin":104,"end":108},"obj":"Body_part"},{"id":"T90","span":{"begin":118,"end":122},"obj":"Body_part"},{"id":"T91","span":{"begin":145,"end":150},"obj":"Body_part"}],"attributes":[{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma67122"},{"id":"A90","pred":"fma_id","subj":"T90","obj":"http://purl.org/sig/ont/fma/fma67122"},{"id":"A91","pred":"fma_id","subj":"T91","obj":"http://purl.org/sig/ont/fma/fma67264"}],"text":"National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T193","span":{"begin":68,"end":69},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T194","span":{"begin":93,"end":100},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T195","span":{"begin":155,"end":156},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T196","span":{"begin":283,"end":285},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T128","span":{"begin":145,"end":150},"obj":"Chemical"},{"id":"T129","span":{"begin":151,"end":154},"obj":"Chemical"},{"id":"T130","span":{"begin":524,"end":526},"obj":"Chemical"}],"attributes":[{"id":"A128","pred":"chebi_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"},{"id":"A129","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A130","pred":"chebi_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T85","span":{"begin":0,"end":561},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"284","span":{"begin":516,"end":526},"obj":"Gene"},{"id":"286","span":{"begin":50,"end":62},"obj":"Species"},{"id":"287","span":{"begin":269,"end":281},"obj":"Species"},{"id":"291","span":{"begin":145,"end":150},"obj":"Chemical"}],"attributes":[{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"Tax:9606"},{"id":"A287","pred":"tao:has_database_id","subj":"287","obj":"Tax:9606"},{"id":"A291","pred":"tao:has_database_id","subj":"291","obj":"MESH:D008055"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).65 The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.66 CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701)."}